Clinical Trial Update: Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial (LUNG-3) is evaluating Zongertinib vs standard treatment in patients with surgically removed non-small cell lung cancer harboring HER2 mutations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Zongertinib (Zongertinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING